Measures of functional status and quality-of-life in schizophrenia

Current Psychiatry Reviews

Volumn 4, Issue 1, 2008, Pages 28-38

  Price, Mark A ^a   Hill, Cheryl D ^a   Williams, Valerie S L ^a   Morlock, Robert J ^b   Leeuwenkamp, Oscar ^c   Patterson, Thomas L ^d  

^a RTI HEALTH SOLUTIONS   (United States)

^b PFIZER INC   (United States)

^c NV ORGANON   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL TRIAL; CONTENT VALIDITY; DAILY LIFE ACTIVITY; EUROQOL-5D; FUNCTIONAL ASSESSMENT; FUNCTIONAL NEEDS ASSESSMENT; FUNCTIONAL STATUS; GLOBAL ASSESSMENT OF FUNCTIONING; GLOBAL ASSESSMENT SCALE; HEALTH CARE QUALITY; HUMAN; INTERNAL CONSISTENCY; LIFE SKILLS PROFILE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MULTNOMAH COMMUNITY ABILITY SCALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; QUALITY OF LIFE INTERVIEW; QUALITY OF WELL-BEING; REHABILITATION CARE; REVIEW; ROLE FUNCTIONING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SHEEHAN DISABILITY SCALE; SHORT FORM 36; SOCIAL ADAPTATION; SOCIAL ADJUSTMENT SCALE; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; SOCIAL FUNCTIONING SCALE; SOCIAL INTERACTION; SOCIAL SKILLS PERFORMANCE ASSESSMENT; SPECIFIC LEVEL OF FUNCTION SCALE; TEST RETEST RELIABILITY; UNIVERSITY OF CALIFORNIA, SAN DIEGO, PERFORMANCE-BASED SKILLS ASSESSMENT; VALIDATION PROCESS; WHO QUALITY OF LIFE SCALE-SHORT FORM;

EID: 41949087274     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340008783743839     Document Type: Review

References (92)

1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2):261-76.
2. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 1989; 25(2): 159-63.
3. Cocns SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17(1): 13-35.
4. Namjoshi MA, Buesching DP. A review of the health-ielated quality of life literature in bipolar disorder. Qual Life Res 2001; 10(2): 105-15.
5. Thompson DR, Yu CM. Quality of life in patients with comnary heart disease-I: Assessment tools. Health Qual Life Outcomes 2003; 1(1); 42.
6. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40(2): 171-8.
7. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2 ed). Hillsdale, NJ. Lawrence Erlbaum Associates, 1988.
8. Joeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10(4): 407-15.
9. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epide miol 1999; 52(9): 861-73.
10. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41(5): 582-92.
11. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56(5): 395-407.
12. American Psychiatric Association. Handbook of psychiatric measures (2 ed). Arlington, VA: American Psychiatric Publishing, Inc., 2000.
13. Velligan DI, Mahurin RK, Diamond PL, et al. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 1997; 25(1): 21-31.
14. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33(6): 766-71.
15. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983; 40(11): 1228-31.
16. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992; 149(9): 1148-56.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision). Washington, DC: American Psychiatric Association, 2000.
18. Rocca P, Bellino S, Calvarese P, et al. Depressive and negative symptoms in schizophrenia: different effects on clinical features. Compr Psychiatry 2005; 46(4):304-10.
19. Fleischhaker C, Schulz E, Tepper K, et al. Long-term course of adolescent schizophrenia. Schizophr Bull 2005; 31(3): 769-80.
20. Thara R. Twenty-year course of schizophrenia: the Madras Longitudinal Study. Can J Psychiatry 2004; 49(8): 564-9.
21. Middelboe T, Maekeprang T, Hansson L, et al. The Nordic Study on schizophrenic patients living in the community. Subjective needs and perceived help. Eur Psychiatry 2001; 16(4): 207-14.
22. Baier M, DeShay F, Owens K, et al. The relationship between insight and clinical factors for persons with schizophrenia. Arch Psychiatr Nurs 2000; 14(6): 259-65.
23. Kampman O, Laippala P, Vaananen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2002; 110(1): 39-48.
24. Bengtsson-Tops A, Hansson L. Subjective quality of life in schizophrenic patients living in the community. Relationship to clinical and social characteristics. Eur Psychiatry 1999; 14(5): 256-63.
25. Rosen A, Hadzi-Pavlovic D, Parker G. The life skills profile: a measure assessing function and disability in schizophrenia. Schizophr Bull 1989; 15(2): 325-37.
26. Browne G, Courtney M. Measuring the impact of housing on people with schizophrenia. Nurs Health Sci 2004; 6(l): 37-44.
27. Parker G, O'Donnell M, Hadzi-Pavlovic D, Proberts M. Assessing outcome in community mental health patients: a comparative analysis of measures. Int J Soc Psychiatry 2002; 48(l): 11-9.
28. Barker S, Barron N, McFarland BH, Bigelow DA. A community ability scale for chronically mentally ill consumers: Part I. Reliability and validity. Community Ment Health J 1994; 30(4): 363-83.
29. Prouteau A, Verdoux H, Briand C, et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res 2005; 77(2-3): 343-53.
30. Prouteau A, Verdoux H, Briand C, et al. The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Res 2004; 129(2): 171-7.
31. Goodman SH, Sewell DR, Cooley EL, Leavitt N. Assessing levels of adaptive functioning: the Role Functioning Scale. Community Ment Health J 1993; 29(2): 119-31.
32. Sergi MJ, Rassovsky Y, Nuechterlein KH, Green MF. Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am J Psychiatry 2006; 163(3): 448-54.
33. Kee KS, Green MF, Mintz J, Brekke JS. Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull 2003; 29(3): 487-97.
34. Leon AC, Shear MK, Portera L, Klerman GL. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992; 27(2): 78-82.
35. Olfson M, Weissman MM, Leon AC, et al. Psychotic symptoms in primary care. J Fam Pract 1996; 43(5): 481-8.
36. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976; 33(9): 1111-5.
37. Cooper P, Osborn M, Gath D, Feggetter G. Evaluation of a modified self-report measure of social adjustment. Br J Psychiatry 1982; 141: 68-75.
38. Patterson TL, Semple SJ, Shaw WS, et al. Self-reported social functioning among older patients with schizophrenia. Schizophr Res 1997; 27(2-3): 199-210.
39. Birchwood M, Smith J, Cochrane R, et al. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry 1990; 157: 853-9.
40. Vazquez Morejon AJ, Jimenez Ga-Boveda R. Social functioning scale: new contributions concerning its psychometric characteristics in a Spanish adaptation. Psychiatry Res 2000; 93(3): 247-56.
41. Torres A, Olivares JM. Validation of the Spanish version of the Social Functioning Scale. Actas Esp Psiquiatr 2005; 33(4): 216-20.
42. Dickerson F, Boronow JJ, Ringel N, Parente F. Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophr Res 1996; 21(2): 75-83.
43. Schneider LC, Struening EL. SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr 1983; 19(3): 9-21.
44. Bartels SJ, Mueser KT, Miles KM. A comparative study of elderly patients with schizophrenia and bipolar disorder in nursing homes and the community. Schizophr Res 1997; 27(2-3): 181-90.
45. Patterson TL, Goldman S, McKibbin CL, et al. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001; 27(2): 235-45.
46. Mausbach BT, Bowie CR, Harvey PD, et al. Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. J Psychiatr Res 2007. (Epub ahead of print).
47. Twamley EW, Doshi RR, Nayak GV, et al. Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am J Psychiatry 2002; 159(12): 2013-20.
48. Bowie CR, Reichenberg A, Patterson TL, et al. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006; 163(3): 418-25.
49. Patterson TL, Moscona S, McKibbin CL, et al. Social skills performance assessment among older patients with schizophrenia. Schizophr Res 2001; 48(2-3): 351-60.
50. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473-83.
51. Ware JE, Snow KK, Kosinski, M. SF-36 health survey: manual and interpretation guide (2 ed). Boston, MA: The Health Institute, New England M,edical Center, 1993.
52. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31(3): 247-63.
53. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scores: a user's manual (2 ed). Boston, MA: The Health Institute, New England Medical Center, 1994.
54. McDowell I, Newell C. Measuring health: a guide to rating scules and questionnaires (2 ed). New York, New York: Oxford University Press, 1996.
55. Hewitt J. Critical evaluation of the use of research tools in evaluating quality of life for people with schizophrenia. Int J Ment Health Nurs 2007; 16(1): 2-14.
56. Tunis SL, Croghan TW, Heilman DK, et al. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 1999; 37(7): 678-91.
57. Russo J, Trujillo CA, Wingerson D, et al. The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients. Med Care 1998; 36(5): 752-6.
58. Fleischhacker WW, Rabinowitz J, Kemmler G, et al. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 2005; 187: 131-6.
59. Sciolla A, Patterson TL, Wetherell JL, et al. Functioning and well-being of middle-aged and older patients with schizophrenia: measurement with the 36-item, short-form (SF-36) health survey. Am J Geriatr Psychiatry 2003; 11 (6): 629-37.
60. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37(1): 53-72.
61. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQoI Group. Health Policy 1990; 16(3): 199-208.
62. Badia X, Roset M, Herdman M, Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001; 21(1): 7-16.
63. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ 1996; 5(2): 141-54.
64. van de Willige G, Wiersma D, Nienhuis FJ, Jenner JA. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qua Life Res 2005; 14(2): 441-51.
65. Prieto L, Novick D, Sacristan JA, et al. A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr Scand Suppl 2003; (416): 24-9.
66. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29(2): 321-6.
67. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000; 61(1): 101-9.
68. Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001; 13(1): 18-27.
69. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-reftactory depression. J Affect Disord 1998; 48(2-3): 157-61.
70. Ritsner M, Kurs R, Gibel A, et al. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res 2005; 14(7); 1693-703.
71. Ritsner MS. Predicting quality of life impairment in chronic schizophrenia from cognitive variables. Qual Life Res 2007; 16(6): 929-37.
72. Lehman AF. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning 1988; 11(1): 51-62.
73. Russo J, Roy-Byrne P, Reeder D, et al. Longitudinal assessment of quality of life in acute psychiatric inpatients: reliability and validity. J Nerv Ment Dis 1997; 185(3): 166-75.
74. Reine G, Simeoni MC, Auquier P, et al. Assessing health-related quality of life in patients suffering from schizophrenia: a comparison of instruments. Eur Psychiatry 2005; 20(7): 510-9.
75. Heinrichs DW, Hanlon TE, Carpenter WT, Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10(3): 388-98.
76. Ritsner M, Kurs R, Ratner Y, Gibel A. Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Psychiatry Res 2005; 135(1): 65-75.
77. Bilker WB, Brensinger C, Kurtz MM, et al. Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology 2003; 28(4): 773-7.
78. Bozikas VP, Kosmidis MH, Kafantari A, et al. Community dysfunction in schizophrenia: rate-limiting factors. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(3): 463-70.
79. Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? J Clin Psychiatry 1999; 60(suppl 5): 22-9, discussion 30.
80. Lysaker PH, Meyer PS, Evans JD, et al. Childhood sexual trauma and psychosocial functioning in adults with schizophrenia. Psychiatr Serv 2001; 52(11): 1485-8.
81. Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis 1984; 37(2): 85-95.
82. Kaplan RM, Ganiats TG, Sieber WJ, Anderson JP. The Quality of Well-Being Scale: critical similarities and differences with SF-36. Int J Qual Health Care 1998; 10(6): 509-20.
83. Patterson TL, Kaplan RM, Grant I, et al. Quality of well-being in late-life psychosis. Psychiatry Res 1996; 63(2-3): 169-81.
84. Kasekow JW, Twamley E, Mulchahey JJ, et al. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Res 2001; 103(1): 69-78.
85. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004; 13(2): 299-310.
86. Wegener S, Redoblado-Hodge MA, Lucas S, et al. Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. Aust N Z J Psychiatry 2005; 39(6): 487-92.
87. Alptekin K, Akvardar Y, Kivircik Akdede BB, et al. Is quality of life associated with cognitive impairment in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(2): 239-44.
88. Grace J, Malloy PF. Frontal systems behavior scale: professional manual (2 ed). Lutz, F1: Psychological Assessment Resources, 2001.
89. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19(8): 787-805.
90. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9(8): 887-900.
91. U.S. Department of Health and Human Services. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. February 2006. Available at: http://www.fda.gov/ cder/guidance/5460dft.pdf
92. Leeuwenkamp O, Velligan DI, Wang M, et al. Association between changes on the Negative Symptom Assessment scale end measures of functional outcome in schizophrenia. Presented at: International Congress on Schizophrenia Research; March 28-April 1, 2007; Colorado Springs, CO.